Diabetic cardiomyopathy from a gut microbiota perspective: research progress and prospects

Yuying Liang; Yan Gao; Wei Wang; Zhuo Zhao

doi:10.3389/fmed.2025.1737326

Diabetic cardiomyopathy from a gut microbiota perspective: research progress and prospects

Front Med (Lausanne). 2026 Jan 12:12:1737326. doi: 10.3389/fmed.2025.1737326. eCollection 2025.

Authors

Yuying Liang¹, Yan Gao², Wei Wang³, Zhuo Zhao⁴

Affiliations

¹ School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
² School of Qingdao University, Qingdao, Shandong, China.
³ Department of Cardiovascular Surgery, Shandong Public Health Clinical Center, Jinan, Shandong, China.
⁴ Department of Cardiovascular Medicine, Jinan Central Hospital, Jinan, Shandong, China.

Abstract

Recent evidence indicates that gut microbiota dysbiosis impairs intestinal barrier function, induces endotoxemia, and consequently triggers systemic inflammatory cascades. Advances in gut microbiota research have further elucidated its critical role in the pathogenesis of diabetes and its complications. This review examines the relationship between diabetic cardiomyopathy and gut microbiota, delineating microbial metabolite-mediated and immunomodulatory influences on myocardial function, while proposing novel therapeutic strategies.

Keywords: diabetes; diabetic cardiomyopathy; gut microbiota; inflammatory; mitochondria dysfunction.

Publication types

Review